Skip to content
Screener

Precigen PGEN Net Change in Cash

Net Change in Cash at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
-$861M-150%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
-$504.6M+53.2%
Gilead Sciences logo
Gilead SciencesGILD
-$4.45B-59.9%
Allogene Therapeutics logo
Allogene TherapeuticsALLO
-$21.38M+34.7%
Apogee Therapeutics, Inc. logo
Apogee Therapeutics, Inc.APGE
$320.25M+1,018%
Regenxbio logo
RegenxbioRGNX
$21.26M

Other financials

Income statement

See full
Revenue$23.3M+1,634%
Operating income-$6.0M+73.5%
Net income-$7.9M+85.4%
EPS (diluted)-$0.02+88.9%

Balance sheet

See full
Cash & equivalents$7.5M+23.5%
Total debt$98.3M+1,714%
Total equity$20.2M+244%
Total assets$138.6M+7.6%

Cash flow

See full
Operating cash flow-$43.8M-168%
CapEx$258.0K-58.5%
Free cash flow-$44.1M-160%

Valuation

See full
Market cap$2.59B+404%
Enterprise value$2.68B+431%
P/S97.5×

Profitability

See full
Gross margin83.6%
Operating margin-2,890.9%
Net margin-3,656%
FCF margin-1,756.5%

Returns & leverage

See full
Return on equity-843.6%-1,103pp
Debt / equity4.9×
Current ratio4.8×+1.3×

Where this comes from

Reported directly by Precigen in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.

The source filing: Precigen’s 10-Q, filed May 13, 2026.

Filed
May 13, 2026, 4:20 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001356090-26-000017
(Amounts in thousands)Three Months Ended March 31, 2026Three Months Ended March 31, 2025
Proceeds from stock option exercises255150
Net cash provided by (used in) financing activities109(679)
Effect of exchange rate changes on cash, cash equivalents, and restricted cash(3)2
Net decrease in cash, cash equivalents, and restricted cash(22,754)(23,459)
Cash, cash equivalents, and restricted cash
Beginning of period30,23429,517
End of period$7,480$6,058
Supplemental disclosure of cash flow information

Item 1. Condensed Consolidated Financial Statements

FAQ

What is Precigen's net change in cash?
Precigen (PGEN) reported net change in cash of -$22.75M in Q1 2026.
How has Precigen's net change in cash changed year-over-year?
Precigen's net change in cash increased by 3.0% year-over-year, from -$23.46M to -$22.75M.
What does net change in cash mean?
Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.

Ask your AI about Precigen's net change in cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude